logo-loader
viewAmryt Pharma PLC

Amryt Pharma to showcase data from successful phase III study at international dermatology conference

The EASE trial of FILSUVEZ showed the gel was effective in accelerating wound healing in people with epidermolysis bullosa, a rare, chronic and distressing genetic skin disorder

Amryt Pharma PLC -
This year's gathering will take place online

Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) said the top-line results from its successful phase III study will be run as a late-breaking abstract at the European Association of Dermatology and Venereology Virtual Congress later this month.

The EASE trial of FILSUVEZ showed the gel was effective in accelerating wound healing in people with epidermolysis bullosa, a rare, chronic and distressing genetic skin disorder.

The treatment has been granted rare paediatric disease designation and has also been given fast track status by the US Food and Drug Administration.

Amryt’s oral presentation will take place on October 31, 2020.

For more details click here.

Quick facts: Amryt Pharma PLC

Price: 196 GBX

AIM:AMYT
Market: AIM
Market Cap: £319.09 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amryt Pharma reports record Q3 2020 results, delivering 19% year on year growth

Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results. The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide. Wiley talks...

4 weeks, 1 day ago

2 min read